#USA #New York #Cancer Treatment #Hoth Therapeutics #HT-001

Hoth Therapeutics to Highlight HT-001 in Upcoming Investor-Focused KOL Event

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, is gearing up to showcase its latest innovation, HT-001, during a significant Key Opinion Leader (KOL) event. Scheduled for June 24, 2025, this event will focus on addressing the pressing issue of skin toxicities caused by cancer treatments, particularly those involving EGFR inhibitors.

The pressing need for a solution stems from the discomforting side effects associated with these therapies, which often force cancer patients to suspend their treatment, jeopardizing their chances of recovery. HT-001 is a novel topical therapy designed to combat these debilitating skin conditions. By alleviating symptoms such as rashes and inflammation, HT-001 aims to significantly enhance the quality of life for patients undergoing critical oncological treatments.

Growth of the Chemotherapy Market

The chemotherapy drug market has seen substantial growth, valued at USD 10.87 billion in 2024 and projected to reach USD 18.35 billion by 2031. As more patients undergo chemotherapy, the demand for supportive care drugs to manage side effects continues to rise. However, existing options are often inadequate. Notably, severe manifestations like Acral erythema, commonly known as hand-foot syndrome, highlight the urgent need for more effective treatments.

Robb Knie, CEO of Hoth Therapeutics, emphasizes the unique position of HT-001 in this landscape. “HT-001 is pioneering a specialized approach to treating skin toxicities linked with EGFR inhibitor therapies. We are thrilled to share compelling case studies and the interim results from our Phase 2a trials, which support HT-001's promising safety profile and its potential to redefine care standards in an area that remains critically underserved,” he states.

Insights from Leading Experts

The KOL event will feature expert commentary from prominent figures in dermatology and dermato-oncology, including Dr. Jonathan Hale Zippin and Dr. Adam Friedman. These experts will discuss not only the substantial clinical needs but also the encouraging early findings pertaining to HT-001’s safety and efficacy, derived from an ongoing open-label cohort trial. As investors and media personnel gather, they will receive exclusive insights into how HT-001 could transform the treatment protocol for cancer patients, potentially serving as a preventive therapy for those on EGFR inhibitors.

In conjunction with its clinical progress, Hoth Therapeutics has also made strides in protecting its intellectual property. The United States Patent and Trademark Office recently acknowledged a filing for a new patent application covering the unique formulation of HT-001, thereby reinforcing the company's strategic market position and expanding its intellectual property portfolio.

Key Highlights of the Event

• - Focus on HT-001's transformative potential for addressing unmet needs in cancer treatment.
• - Strengthening of intellectual property strategy surrounding HT-001.
• - Presentation of compelling data showcasing HT-001’s mechanism of action against EGFR inhibitor-induced toxicities.
• - Update on Hoth's pipeline progress and ongoing Phase 2 trial to be shared.

This event represents an opportunity for investors, healthcare professionals, and interested media to delve deeper into Hoth Therapeutics’ innovative approaches and their implications for patient care. Details regarding participation will be released as the event date approaches.

As the need for effective cancer treatment solutions escalates, Hoth Therapeutics positions itself at the forefront of this critical sector, committed to improving the lives of patients throughout their cancer journey. To learn more about Hoth Therapeutics and its mission, please visit Hoth Therapeutics.